| 2022-05-13 |
复牌提示：
2022-05-12 19:50:26 停牌，复牌日期 2022-05-16 00:00:01
|
| 2022-05-13 |
详情>>
内部人交易：
Mead Dana G Jr.等共交易18笔
|
| 2022-05-04 |
详情>>
股本变动：
变动后总股本3381.37万股
|
| 2022-05-04 |
详情>>
业绩披露：
2022年一季报每股收益-0.85美元,归母净利润-2880.4万美元,同比去年增长-43.8%
|
| 2022-03-08 |
详情>>
业绩披露：
2021年年报每股收益-4.8美元,归母净利润-1.6亿美元,同比去年增长-120.74%
|
| 2022-03-08 |
详情>>
业绩披露：
2019年年报每股收益-1.37美元,归母净利润-4299.4万美元,同比去年增长-87.57%
|
| 2021-11-02 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-2.06美元,归母净利润-6848.1万美元,同比去年增长-31.39%
|
| 2021-09-07 |
股东大会：
将于2021-10-08召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated August 6, 2021, (the “Merger Agreement”), by and among Intersect ENT, Medtronic, Inc. (“Parent”), and Project Kraken Merger Sub, Inc. (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into Intersect ENT, with Intersect ENT continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the “Merger”);
2.To consider and vote on the proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to Intersect ENT’s named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement (the “Compensation Proposal”);
3.To consider and vote on any proposal to adjourn the Special Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-06 |
详情>>
业绩披露：
2021年中报每股收益-1.11美元,归母净利润-3663.2万美元,同比去年增长9.90%
|
| 2021-08-06 |
财报披露：
美东时间 2021-08-06 盘前发布财报
|
| 2021-05-10 |
详情>>
业绩披露：
2021年一季报每股收益-0.61美元,归母净利润-2003.1万美元,同比去年增长-14.25%
|
| 2021-04-20 |
股东大会：
将于2021-06-03召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees for director named in the Proxy Statement accompanying this notice to serve until the next annual meeting or their successors are duly elected and qualified.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021.
3.To provide an advisory vote on executive compensation, as described in the Proxy Statement accompanying this notice.
4.To conduct any other business properly brought before the annual meeting.
|
| 2021-03-09 |
详情>>
业绩披露：
2020年年报每股收益-2.22美元,归母净利润-7231.9万美元,同比去年增长-68.21%
|
| 2020-11-02 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-1.6美元,归母净利润-5212.2万美元,同比去年增长-48.76%
|
| 2020-08-05 |
详情>>
业绩披露：
2020年中报每股收益-1.25美元,归母净利润-4065.7万美元,同比去年增长-83.23%
|
| 2020-05-11 |
详情>>
业绩披露：
2020年一季报每股收益-0.54美元,归母净利润-1753.3万美元,同比去年增长-62.27%
|
| 2020-04-29 |
股东大会：
将于2020-06-04召开股东大会
会议内容 ▼▲
- 1.elect the Board of Directors’ nominees Kieran T. Gallahue, Teresa L. Kline, Cynthia L. Lucchese, Dana G. Mead, Jr., Frederic H. Moll, M.D., W. Anthony Vernon and myself as directors of Intersect ENT, each to serve until the next annual meeting or a successor is duly elected and qualified;
2.ratify the selection by the Audit Committee and the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020;
3.amend our Certificate of Incorporation to add a federal forum selection provision;
4.provide an advisory vote on Intersect ENT’s executive compensation, as described in the Proxy Statement
5.conduct any other business properly brought before the meeting.
|
| 2020-02-27 |
详情>>
业绩披露：
2018年年报每股收益-0.75美元,归母净利润-2292.2万美元,同比去年增长-40.08%
|
| 2019-04-23 |
股东大会：
将于2019-06-04召开股东大会
会议内容 ▼▲
- 1.elect the Board of Directors’ nominees Kieran T. Gallahue, Teresa L. Kline, Cynthia L. Lucchese, Dana G. Mead, Jr., Frederic H. Moll, M.D., W. Anthony Vernon and myself as directors of Intersect ENT, each to serve until the next annual meeting or a successor is duly elected and qualified;
2.ratify the selection by the Audit Committee and the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019;
3.provide an advisory vote on Intersect ENT’s executive compensation, as described in the Proxy Statement;
4.conduct any other business properly brought before the meeting.
|
| 2018-04-23 |
股东大会：
将于2018-06-05召开股东大会
会议内容 ▼▲
- 1. To elect the seven nominees for director named in the proxy statement accompanying this notice to serve until the next annual meeting or their successors are duly elected and qualified.
2. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
3. To approve an amendment to our 2014 Employee Stock Purchase Plan to increase the number of shares available for issuance by 1,200,000 shares.
4. To provide an advisory vote on executive compensation, as described in the Proxy Statement accompanying this Notice.
5. To conduct any other business properly brought before the annual meeting.
|
| 2017-04-19 |
股东大会：
将于2017-06-01召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees for director named in the proxy statement accompanying this notice to serve until the next annual meeting and their successors are duly elected and qualified.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
3.To provide an advisory vote on executive compensation, as described in the Proxy Statement accompanying this Notice.
4.To conduct any other business properly brought before the annual meeting.
|
| 2016-04-20 |
股东大会：
将于2016-06-02召开股东大会
会议内容 ▼▲
- 1. To elect the seven nominees for director named in the proxy statement accompanying this notice to serve until the next annual meeting and their successors are duly elected and qualified.
2. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
3. To provide an advisory vote on executive compensation, as described in the Proxy Statement accompanying this Notice.
4. To provide an advisory vote on the frequency of future advisory votes on executive compensation.
5. To conduct any other business properly brought before the annual meeting.
|
| 2015-04-22 |
股东大会：
将于2015-06-04召开股东大会
会议内容 ▼▲
- 1. To elect the seven nominees for director named in the proxy statement accompanying this notice to serve until the next annual meeting and their successors are duly elected and qualified.
2. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
3. To conduct any other business properly brought before the annual meeting.
|